Business Wire

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)

MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals ...
Business Insider

Halda Therapeutics Announces Oral Plenary Presentation on HLD-0915 Clinical Data in Metastatic Castration-Resistant Prostate Cancer (mCRPC) at 2025 AACR-NCI-EORTC International ...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...
Seeking Alpha

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.
Morningstar

Plenary Presentation at The ASTRO Meeting by TGH Cancer Institute Member Dr. Rodney Ellis Demonstrated That Short-course Radiation Improves Quality of Life for Men with ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...
Business Wire

Artera Announces Two Presentations at ASTRO 2024 Validating its MMAI Platform to Inform Treatment Decisions for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present two oral abstracts at the 2024 American ...